Form 4 for VCYT VERACYTE, INC.
Accepted 2022-03-07 00:00:00 ET · period of report 2022-03-03 · accession 0001384101-22-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-07 | 2022-03-03 | VCYT | Stapley Marc | CEO, Dir | A - Grant | $0.00 | +56.5K | 103.8K | +120% | $0 |
| D | 2022-03-07 | 2022-03-03 | VCYT | Stapley Marc | CEO, Dir | A - Grant | $0.00 | +103.0K | 103.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-03 | A | A | 56,537 | $0.00 | 103,808 | D | — | — | (F2) Includes 464 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan on January 31, 2022. |
| 2 | Derivative | Stock Option (right to buy) | 2022-03-03 | A | A | 103,026 | $0.00 | 103,026 | D | $26.02 · — to 2032-03-03 | 103,026 Common Stock | (F3) The option becomes exercisable as to 25% of the shares on March 3, 2023, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. |